文献速递神经肌肉病

巴托利单抗对比安慰剂治疗全身型肌无力:一项随机临床试验

Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-03-04

这项多中心随机临床试验在中国27个中心纳入132例抗体阳性全身型肌无力成人患者,比较巴托利单抗与安慰剂联合标准治疗的疗效与安全性。结果显示巴托利单抗组第一周期持续MG-ADL改善率高于安慰剂组(58.2% vs 31.3%,OR 3.45,95%CI 1.62-7.35,P=0.001),且耐受性良好。

要点

  • 巴托利单抗组第一周期持续MG-ADL改善率为58.2%,安慰剂组为31.3%(OR 3.45,95%CI 1.62-7.35,P=0.001)。
  • 两组MG-ADL评分最早在第2周出现分离,末次给药后1周(第43天)组间差异为-1.9(95%CI -2.8至-1.0,名义P<0.001)。
  • 治疗相关不良事件发生率巴托利单抗组70.1%、安慰剂组36.9%;严重治疗中出现的不良事件分别为3.0%和7.7%。

核心结论

  • 巴托利单抗提高了全身型肌无力成人患者的持续MG-ADL改善率,且耐受性良好。
  • 其临床效应和IgG降低程度与既往报道的艾加莫德和罗扎奈利珠单抗相似。
  • 需要未来大样本研究以进一步了解巴托利单抗的安全性特征。

研究设计与样本

  • 多中心随机临床试验,于2021年9月15日至2022年6月29日在中国27个中心开展。
  • 筛选178例18岁及以上全身型肌无力成人患者,132例随机分组,其中131例抗体阳性、1例抗体阴性。
  • 132例入组患者平均(SE)年龄43.8(13.6)岁,女性88例(67.2%)。
  • 每周期为6次每周皮下注射巴托利单抗680 mg或匹配安慰剂,随后观察4周;需要持续治疗者进行第二周期。

主要发现

  • 抗体阳性患者第一周期持续MG-ADL改善率:安慰剂组31.3%(20/64)vs 巴托利单抗组58.2%(39/67),OR 3.45(95%CI 1.62-7.35,P=0.001)。
  • 两组MG-ADL评分最早在第2周出现分离。
  • MG-ADL评分降低的最大平均(SE)组间差异出现在末次给药后1周(第43天):安慰剂组1.7(0.3)vs 巴托利单抗组3.6(0.3),组间差异-1.9(95%CI -2.8至-1.0,名义P<0.001)。
  • 治疗相关不良事件发生率:安慰剂组36.9%(24/65)vs 巴托利单抗组70.1%(47/67)。
  • 严重治疗中出现的不良事件发生率:安慰剂组7.7%(5/65)vs 巴托利单抗组3.0%(2/67)。

关键数值与推荐

  • 主要结局为第一周期中MG-ADL评分较基线降低3分或以上并持续4周或以上,分析人群为乙酰胆碱受体或肌肉特异性激酶抗体阳性者。
  • 巴托利单抗给药方案为每周期6次每周皮下注射680 mg,随后观察4周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要未来大样本研究以进一步了解巴托利单抗的安全性特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Myasthenia gravis (MG) is caused by autoantibodies that disrupt the neuromuscular junction. The neonatal fragment crystallizable receptor (FcRn) antagonists, efgartigimod and rozanolixizumab, reduce immunoglobulin G (IgG) level in the circulation and alleviate symptoms in patients with generalized MG. OBJECTIVE: To examine the efficacy and safety profile of batoclimab, a monoclonal IgG1 antibody, in patients with generalized MG. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter randomized clinical trial conducted from September 15, 2021, to June 29, 2022, at 27 centers in China. Adult patients 18 years or older with generalized MG were screened, and those who were antibody positive were enrolled. INTERVENTION: Eligible patients received batoclimab or matching placebo in addition to standard of care. Each treatment cycle consisted of 6 weekly subcutaneous injections of batoclimab, 680 mg, or matching placebo followed by 4 weeks of observation. A second treatment cycle was conducted in patients who required continuing treatment. MAIN OUTCOME AND MEASURE: The primary outcome was sustained improvement, as defined by a 3-point or greater reduction in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline for 4 or more consecutive weeks in the first cycle in individuals who were positive for acetylcholine receptor or muscle-specific kinase antibodies. RESULTS: A total of 178 adult patients with generalized MG were screened, 132 were randomly assigned, 131 tested positive for antibodies, and 1 tested negative for antibodies. A total of 132 patients (mean [SE] age, 43.8 [13.6] years; 88 women [67.2%]) were enrolled. The rate of sustained MG-ADL improvement in the first cycle in antibody-positive patients was 31.3% (20 of 64) in the placebo group vs 58.2% (39 of 67) in the batoclimab group (odds ratio, 3.45; 95% CI, 1.62-7.35; P = .001). The MG-ADL score diverged between the 2 groups as early as week 2. The mean (SE) maximum difference in MG-ADL score reduction occurred 1 week after the last dose (day 43, 1.7 [0.3] in the placebo group vs 3.6 [0.3] in the batoclimab group; group difference, -1.9; 95% CI, -2.8 to -1.0; nominal P < .001). The rates of treatment-related and severe treatment-emergent adverse events in patients were 36.9% (24 of 65) and 7.7% (5 of 65) in the placebo group vs 70.1% (47 of 67) and 3.0% (2 of 67) in the batoclimab group, respectively. CONCLUSIONS AND RELEVANCE: Batoclimab increased the rate of sustained MG-ADL improvement and was well tolerated in adult patients with generalized MG. Clinical effects and the extent of IgG reduction were similar to those previously reported for efgartigimod and rozanolixizumab. Future studies of large sample size are needed to further understand the safety profile of batoclimab. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05039190.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Yan C, Yue Y, Guan Y, et al. Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38436998. doi:10.1001/jamaneurol.2024.0044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。